AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06632223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory motor training
Description: Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.
Study NCT06632223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
Study NCT06632223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
Study NCT05420714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom Professional Continuous Glucose Monitoring
Description: Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
Study NCT05272137 — intervention group
Intervention type: DEVICE
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
Study NCT05231577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7.5fr ultra-fine ureteroscopy
Description: The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
Study NCT05231577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9.2fr Ureteroscopy
Description: The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
Study NCT04644796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
Study NCT04644796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
Study NCT05557461 — intervention group
Intervention type: DEVICE
Intervention: End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility
Description: (0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test.
Study NCT06391281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
Study NCT04802239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical hypnosis group
Description: Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques.
Study NCT04802239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calm wake group
Description: healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
Study NCT06261554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Low dose OIT
Description: Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
Study NCT06087107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Spinal Decompression Exercises
Description: The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
Study NCT06087107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eldoa
Description: The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
Study NCT06197854 — intervention group
Intervention type: PROCEDURE
Intervention: Hernioplasty
Description: Surgical hernioplasty
Study NCT04980690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.
Study NCT05636384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based care
Description: Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit
Study NCT05480436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coadministration
Description: the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
Study NCT05480436 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
Study NCT05480436 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV4+PPV23
Description: received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
Study NCT04359433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week
Study NCT04519151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered by IV infusion on Day 1 of each 21-day cycle.
Study NCT04519151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg administered orally (PO) QD during each 21-day cycle.
Study NCT05076526 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (Synolis VA)
Description: Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat
Study NCT05076526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)
Description: The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)
Study NCT05948254 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triple function scan body
Description: The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
Study NCT06466122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06466122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT06466122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT06466122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06466122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given PO
Study NCT06466122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04960150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press tack needle
Description: Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm
Study NCT04960150 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plesterin
Description: Plesterin
Study NCT04474847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
Study NCT04474847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
Study NCT04914104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training - Headspace App
Description: The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
Study NCT06131307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Education
Description: Paternalistic leadership training will be given to clinical manager nurses.
Study NCT04977908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin
Study NCT04977908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin pump therapy with CGM
Description: Participants usual insulin pump therapy with Dexcom G6 CGM
Study NCT06249815 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
Study NCT06249815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
Study NCT06325748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SENTI-202
Description: SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.~SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles to achieve optimal response with the optionality of an additional consolidation cycle thereafter. Additional dosing schedules may be explored depending on study data.
Study NCT06328114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
Study NCT05714813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Speed Circuit Resistance Training
Description: Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
Study NCT05714813 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lecture on Diet, Exercise and Cognition
Description: Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
Study NCT04676646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Investigational medicinal product
Study NCT04676646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator
Study NCT04676646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained.
Study NCT05360511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: particulate xenograft + erythropoietin gel.
Description: 1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect.
Study NCT05360511 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: particulate xenograft
Description: * All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect.
Study NCT05782608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ibuprofen
Description: Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
Study NCT05782608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketorolac
Description: Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
Study NCT05061810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone application self-management programme
Description: The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
Study NCT05061810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone application self-management programme
Description: The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
Study NCT06314568 — intervention group
Intervention type: RADIATION
Intervention: Radiochemotherapy plus interventional radiotherapy
Description: All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
Study NCT06328114 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
Study NCT05028933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPCAM CAR-T
Description: Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
Study NCT06384274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
Study NCT06384274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
Study NCT06159205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard exercises
Description: Standard exercises for TKA patients.
Study NCT06159205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: Core stability exercises for TKA patients.
Study NCT05460273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan (Dato-DXd)
Description: Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
Study NCT04942340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atipamezole & Caffeine
Description: In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
Study NCT04942340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride & Saline
Description: In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
Study NCT05653687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy
Description: Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
Study NCT06295263 — intervention group
Intervention type: OTHER
Intervention: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers
Description: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
Study NCT05337007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: 48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45